Dr Helen Bright
Dr Helen Bright is an esteemed virologist and immunologist with more than 30 years of experience in infectious diseases within the biopharmaceutical industry. In her role as CSO at Centauri Therapeutics, Dr Bright has shaped the scientific strategy behind the company’s therapeutic pipeline, including clinical candidate CTX-187, as well as leading the research and development of the Alphamer platform.
Throughout her career, Dr Bright has held senior scientific and operational leadership positions at AstraZeneca, Pfizer and GSK, where she supported the advancement of novel small molecule, antibody and vaccine candidates from discovery through to the clinic and commercial launch.
Dr Bright was also previously Head of Infection Biology at Medicines Discovery Catapult, where she supported UK academic and SME innovators in the discovery and development of novel anti-infectives, vaccines and diagnostics. Dr Bright holds a PhD in Virology and Immunology from Newcastle University.
Contact info
ArticleWhen antibiotics are not enough: the case for immune-engaging therapies
As antimicrobial resistance grows and patient populations become more complex, the limitations of antibiotics are becoming harder to ignore. Dr Helen Bright, CSO at Centauri Therapeutics, discusses a new approach that targets both the pathogen and the host.